PMID- 2501021
OWN - NLM
STAT- MEDLINE
DCOM- 19890825
LR  - 20111117
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 49
IP  - 15
DP  - 1989 Aug 1
TI  - Caloric restriction and 7,12-dimethylbenz(a)anthracene-induced mammary tumor 
      growth in rats: alterations in circulating insulin, insulin-like growth factors I 
      and II, and epidermal growth factor.
PG  - 4130-4
AB  - Caloric restriction (CR) inhibits many neoplastic diseases in rodents, yet the 
      biochemical mechanism(s) for these effects are poorly understood. We have 
      examined the effects of ad libitum (AL) feeding with 25 or 40% CR on the 
      promotion of 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in 
      virgin female Sprague-Dawley rats. Further, we have also studied the influence of 
      chronic CR on temporal alterations in circulating insulin, insulin-like growth 
      factor I/somatomedin C, insulin-like growth factor II/multiplication-stimulating 
      activity, and epidermal growth factor levels at 0, 1, 3, 5, 11, and 20 weeks in 
      carcinogen- and vehicle-treated animals. Tumor incidence and multiplicity were 
      markedly inhibited (P less than 0.05) with increasing CR. Fasting serum 
      insulin-like growth factor I/somatomedin C levels exhibited a significant acute 
      decline with CR at 1 and 3 weeks, but were comparable to AL-fed controls 
      throughout the remainder of the 5-month study, despite continued differences in 
      weight gain between AL and CR rats. Levels of insulin-like growth factor 
      II/multiplication-stimulating activity exhibited no discernible pattern in 
      relation to CR. Serum insulin levels showed age-dependent increases, but were 
      affected by increasing CR at all time points. Insulin levels were significantly 
      (P less than 0.05) reduced in 40% CR rats from 3 weeks onward compared to 
      controls, while 25% CR resulted in nonsignificant (P less than 0.07) reductions 
      throughout the study. No significant differences in growth factor levels were 
      observed between 7,12-dimethylbenz(a)anthracene- and vehicle-treated rats. 
      Circulating epidermal growth factor was not detectable in any treatment group 
      regardless of the nature or duration of the dietary regimen, time of blood 
      collection, or subsequent tumor-bearing status. These data suggest that decreased 
      serum insulin-like growth factor I/somatomedin C and insulin levels with CR and 
      their complex interactions in vivo may play a role in the inhibition of mammary 
      tumor promotion by CR.
FAU - Ruggeri, B A
AU  - Ruggeri BA
AD  - Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania 19104.
FAU - Klurfeld, D M
AU  - Klurfeld DM
FAU - Kritchevsky, D
AU  - Kritchevsky D
FAU - Furlanetto, R W
AU  - Furlanetto RW
LA  - eng
GR  - CA-09485/CA/NCI NIH HHS/United States
GR  - CA-38981/CA/NCI NIH HHS/United States
GR  - CA-43856/CA/NCI NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Insulin)
RN  - 0 (Somatomedins)
RN  - 57-97-6 (9,10-Dimethyl-1,2-benzanthracene)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 67763-97-7 (Insulin-Like Growth Factor II)
RN  - 9002-62-4 (Prolactin)
SB  - IM
MH  - 9,10-Dimethyl-1,2-benzanthracene
MH  - Animals
MH  - *Energy Intake
MH  - Epidermal Growth Factor/*blood
MH  - Female
MH  - Insulin/*blood
MH  - Insulin-Like Growth Factor I/*blood
MH  - Insulin-Like Growth Factor II/*blood
MH  - Mammary Neoplasms, Experimental/blood/pathology/*prevention & control
MH  - Prolactin/blood
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Somatomedins/*blood
EDAT- 1989/08/01 00:00
MHDA- 1989/08/01 00:01
CRDT- 1989/08/01 00:00
PHST- 1989/08/01 00:00 [pubmed]
PHST- 1989/08/01 00:01 [medline]
PHST- 1989/08/01 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1989 Aug 1;49(15):4130-4.